Who Paid My Doc
Gregory Almony
Cardiovascular Disease Ogden, UT Medical Doctor
NPI 1023003142 CMS profile 137322
5405 S 500 E, Suite #204, Ogden, UT 84405
General payments
$253
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Gregory Almony of Ogden, UT is reported in the CMS Open Payments database as having received $253 across 12 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 19th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $46 | 2 | |
| 2023 | General | $95 | 5 | |
| 2022 | General | $23 | 1 | |
| 2021 | General | $36 | 2 | |
| 2019 | General | $54 | 2 |
Beside peers
- Gregory Almony
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Gregory Almony were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Gregory Almony | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $54 | $450 | $127–$1,392 | $163 |
| 2020 | $0 | $242 | $77–$751 | $114 |
| 2021 | $36 | $335 | $101–$1,037 | $132 |
| 2022 | $23 | $395 | $121–$1,211 | $149 |
| 2023 | $95 | $443 | $136–$1,283 | $160 |
| 2024 | $46 | $450 | $136–$1,323 | $164 |
| 2025 | $0 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 46 drugsPart D claims
4,968
Drug cost
$563,988
Branded share of claims
19.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 219 | $206,070 | |
| Entresto Sacubitril/Valsartan | Brand | 90 | $107,241 | |
| Xarelto Rivaroxaban | Brand | 70 | $71,720 | |
| Jardiance Empagliflozin | Brand | 73 | $48,883 | |
| Farxiga Dapagliflozin Propanediol | Brand | 49 | $46,840 | |
| Repatha Syringe Evolocumab | Brand | 17 | $14,257 | |
| Brilinta Ticagrelor | Brand | 20 | $10,435 | |
| Rosuvastatin Calcium | Generic | 514 | $7,040 | |
| Praluent Pen Alirocumab | Brand | 13 | $6,655 | |
| Ezetimibe | Generic | 298 | $6,271 |
The 10 drugs with the highest cost, of 46 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 45 billing codesPaid by Medicare
$104,626
Medicare patients
1,085
Services billed
2,620
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 51% | |
| Ischemic heart disease | 50% | |
| Diabetes | 38% | |
| Chronic kidney disease | 37% | |
| Atrial fibrillation | 36% | |
| Heart failure | 32% | |
| Depression | 27% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
12 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Utah
John Ryan
Cardiovascular Disease · Salt Lake City, UT
Robert Fowles
Cardiovascular Disease · Salt Lake City, UT
Brian Whisenant
Cardiovascular Disease · Murray, UT
Andrew Behunin
Cardiovascular Disease · Draper, UT
Jeffrey Osborn
Cardiovascular Disease · Salt Lake City, UT
James Fang
Cardiovascular Disease · Salt Lake City, UT
Related records
Cardiovascular Disease in Utah
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Utah
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.